Head-To-Head Contrast: Coherus BioSciences (CHRS) vs. The Competition

Coherus BioSciences (NASDAQ: CHRS) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Coherus BioSciences to similar companies based on the strength of its risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Coherus BioSciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coherus BioSciences -73.89% -307.41% -63.38%
Coherus BioSciences Competitors -4,766.74% -354.83% -43.39%

Analyst Ratings

This is a breakdown of current ratings for Coherus BioSciences and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coherus BioSciences 0 0 9 0 3.00
Coherus BioSciences Competitors 1377 4466 12290 311 2.63

Coherus BioSciences presently has a consensus price target of $34.78, indicating a potential upside of 167.52%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.24%. Given Coherus BioSciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus BioSciences is more favorable than its rivals.

Valuation and Earnings

This table compares Coherus BioSciences and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Coherus BioSciences $165.24 million -$111.05 million -4.89
Coherus BioSciences Competitors $464.68 million $167.54 million -6.57

Coherus BioSciences’ rivals have higher revenue and earnings than Coherus BioSciences. Coherus BioSciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Coherus BioSciences has a beta of 4.32, indicating that its share price is 332% more volatile than the S&P 500. Comparatively, Coherus BioSciences’ rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.

Institutional & Insider Ownership

78.2% of Coherus BioSciences shares are held by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 26.3% of Coherus BioSciences shares are held by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Coherus BioSciences beats its rivals on 7 of the 12 factors compared.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company’s product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply